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ABSTRACT
Introduction: This study evaluates long-term
outcomes of two trabecular micro-bypass stents,
one suprachoroidal stent, and postoperative
prostaglandin in eyes with refractory open an-
gle glaucoma (OAG).
Methods: Prospective ongoing 5-year study of
80 eligible subjects (70 with 4-year follow-up)
with OAG and IOP C 18 mmHg after prior
trabeculectomy and while taking 1–3 glaucoma
medications. Subjects received two iStent tra-
becular micro-bypass stents, one iStent Supra
suprachoroidal stent, and postoperative travo-
prost. Postoperative IOP was measured with
medication and annually following medication
washouts. Performance was measured by the
proportion of eyes with C 20% IOP reduction
on one medication (the protocol-specified
prostaglandin) versus preoperative medicated
IOP (primary outcome); and the proportion of
eyes with postoperative IOP B 15
and B 18 mmHg on one medication (secondary
outcome). Additional clinical and safety data
included medications, visual field, pachymetry,
gonioscopy, adverse events, visual acuity, and
slit-lamp and fundus examinations.
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Results: Preoperatively, mean medicated IOP
was 22.0 ± 3.1 mmHg on 1.2 ± 0.4 medications,
and mean unmedicated IOP was
26.4 ± 2.4 mmHg. Postoperatively, among eyes
without later cataract surgery, mean medicated
IOP at all visits through 48 months
was B 13.7 mmHg (C 37% reduction), and
annual unmedicated IOP was B 18.4 mmHg
(reductions of C 30% vs. preoperative unmedi-
cated IOP and C 16% vs. preoperative medi-
cated IOP). At all postoperative visits among
eyes without additional surgery or medica-
tion, C 91% of eyes had C 20% IOP reduction
on one medication versus preoperative medi-
cated IOP. At month 48, 97 and 98% of eyes
achieved IOP B 15 and B 18 mmHg, respec-
tively, on one medication. Six eyes required
additional medication, no eyes required addi-
tional glaucoma surgery, and safety measure-
ments were favorable throughout follow-up.
Conclusion: IOP control was achieved safely
with two trabecular micro-bypass stents, one
suprachoroidal stent, and postoperative pros-
taglandin. This microinvasive, ab interno
approach introduces a possible new treatment
option for refractory disease.
Trial Registration: NCT01456390.
Funding: Glaukos Corporation.
Keywords: Glaucoma; iStent; iStent Supra;
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INTRODUCTION
Glaucoma is a leading cause of blindness
worldwide, and its management requires per-
sistent lifelong therapy. Within the United
States, primary open angle glaucoma (OAG)
affects approximately 2.71 million people and is
the cause of legal blindness in 5.2% of Cau-
casian and 18.8% of African American individ-
uals [1, 2]. The therapeutic goal of various
treatments—such as topical medications, laser
procedures, microinvasive glaucoma surgery
(MIGS), or traditional filtering surgery—is to
reduce intraocular pressure (IOP) in order to
prevent damage to the optic nerve. Over the
past decade, MIGS procedures with implanta-
tion of trabecular micro-bypass stents have
reduced IOP by connecting the anterior cham-
ber with Schlemm’s canal, thereby bypassing
the damaged trabecular meshwork. Numerous
studies have assessed outcomes for up to 5 years
following implantation of the first FDA-ap-
proved trabecular micro-bypass device, the
iStent Trabecular Micro-Bypass (Glaukos, San
Clemente, CA, USA). These data have demon-
strated that implanting single [3–10] or multiple
[11–15] first-generation iStent devices, either
with or without cataract surgery, can provide
long-term IOP and medication reduction in
patients with mild to moderate glaucoma. In
addition, more recent studies have reported
similarly positive outcomes with second-gener-
ation iStent inject Trabecular Micro-Bypass
devices (Glaukos) implanted with cataract sur-
gery or in a sole procedure [16–20]. Further-
more, MIGS procedures with these stents have
demonstrated a favorable risk profile when
compared with that of traditional filtering
surgeries [21–24].
Until now, trabecular micro-bypass stents
have been used primarily for mild to moderate
OAG. Meanwhile, for more severe OAG,
including refractory cases, treatments have
typically involved incisional glaucoma surgeries
such as trabeculectomy or tube shunts, with
attendant immediate and long-term risks of
sequelae such as endophthalmitis, hypotony,
bleb leaks, fibrosis, and bleb infections [21–30].
In more recent years, however, emerging liter-
ature has pointed to the potential utility of
trabecular micro-bypass stents for these more
advanced glaucoma cases [7, 8, 31–33]. Going
one step further, some recent studies have
examined the effect of simultaneously increas-
ing two forms of outflow via two proven treat-
ment modalities (conventional outflow via
trabecular micro-bypass, and both uveoscleral
and conventional outflow via a prostaglandin
analogue) [15, 20, 34]. In two such studies by
the MIGS Study Group, substantial IOP and
medication reductions were demonstrated
through 36 months following treatment with
two trabecular stents (either iStent [15, 34] or
iStent inject [20]) together with postoperative
daily travoprost in eyes with OAG not
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controlled on two ocular hypotensive medica-
tions. These data have suggested that reduced
IOP and medication burden may be achieved by
a minimally invasive approach.
Building upon these studies of the dual-out-
flow, dual-modality concept to facilitate both
trabecular and uveoscleral outflow, the present
study examined the utility of further bolstering
uveoscleral outflow via a third modality, the
iStent Supra suprachoroidal stent (Glaukos).
Specifically, we evaluated outcomes through 4
years following treatment with two iStent tra-
becular micro-bypass stents, one iStent Supra
suprachoroidal stent, and daily postoperative
prostaglandin in eyes with refractory OAG (de-
fined as eyes with history of prior incisional
glaucoma surgery and with uncontrolled IOP
on one to three medications). Earlier reports
from this study showed that this treatment
strategy could reduce mean IOP by 30–40% in
these eyes, with a favorable safety profile
[35–38].
With the limited choices available for treat-
ment of refractory glaucoma, finding alternate
approaches to prevent vision loss, particularly
approaches with less collateral ocular tissue
damage and lower complication rates, is a
valuable goal of the ophthalmology commu-
nity. Since MIGS with ab interno glaucoma
devices potentially could meet these require-
ments, the present report contributes needed
data on the role of MIGS within this refractory
setting. This study tests the hypothesis that
treatment with two trabecular micro-bypass
stents, one suprachoroidal stent, and postoper-
ative prostaglandin is able to safely produce
long-term IOP and medication reductions in
post-trabeculectomy refractory glaucoma cases.
METHODS
Study Design
This study was a prospective, single-arm, open-
label study of the safety and utility of a new
treatment approach for refractory glaucoma.
The treatment included the implantation of two
iStents (Glaukos) and one iStent Supra (Glau-
kos), and a daily postoperative prostaglandin,
travoprost. For the purposes of the study,
refractory glaucoma was defined as uncon-
trolled IOP despite prior trabeculectomy or tube
shunt surgery and treatment with one to three
ocular hypotensive medications; this definition
is consistent with the American National Stan-
dard for Ophthalmic Glaucoma Devices [39].
A total of 14 visiting MIGS Study Group
surgeons from six countries (US, Canada, UK,
Germany, Spain, Italy) and one staff surgeon
(Armenia) participated in the study. All sur-
geons were trained on surgical technique for
iStent and iStent Supra implantation and on the
study protocol. All surgeries and follow-up visits
were completed at the S.V. Malayan Ophthal-
mological Center in Yerevan, Armenia, and
Ethics Committee approval was provided by the
Armenian Ministry of Health. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (Armenian Ministry of
Health) and with the Helsinki Declaration of
1964, as revised in 2013. Informed consent was
obtained from all patients for being included in
the study. The study registration number is
NCT01456390 (ClinicalTrials.gov).
The study was designed to enroll 80 eyes of
80 phakic or pseudophakic subjects with OAG
(including pseudoexfoliative), history of filter-
ing surgery (trabeculectomy or tube shunt),
current treatment with one to three medica-
tions, and cup-to-disc (C:D) ratio of 0.9 or less.
Exclusion criteria included a history of prior
trabecular stent implantation, argon laser tra-
beculoplasty (ALT), or refractive surgery, or a
history of selective laser trabeculoplasty (SLT)
within 90 days prior to screening. Subjects were
also excluded if they had abnormal angle anat-
omy (e.g., peripheral anterior synechiae), cor-
neal dystrophy or opacity, or best-corrected
visual acuity (BCVA) worse than 20/200 in
either eye. Preoperative IOP requirements
included medicated IOP C 18 and B 45 mmHg,
and unmedicated (post-washout) IOP C 21
and B 45 mmHg.
Performance measures assessed at each visit
included IOP measured by Goldmann applana-
tion, and ocular hypotensive medication use.
Additionally, each subject completed annual
1-month washouts of medications, with
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unmedicated evaluations conducted at months
13, 25, 37, and 49. Treatment effectiveness was
evaluated by the proportion of eyes with C 20%
IOP reduction on one medication (the protocol-
specified prostaglandin) at 4 years versus pre-
operative medicated IOP (primary outcome),
and the proportion of eyes with 4-year postop-
erative IOP B 15 and B 18 mmHg on one medi-
cation (secondary outcome). Proportional
analyses also were performed at annual post-
washout visits to determine the percentages of
eyes with unmedicated IOP reduction of C 20%
versus baseline unmedicated IOP. For continu-
ous variables such as IOP at each visit, descrip-
tive analyses included mean and standard
deviation. IOP data from subjects who under-
went cataract surgery were excluded from IOP
analyses after such surgery. Subjects who
underwent any additional surgery (including
cataract or glaucoma surgery) were to be exclu-
ded from mean IOP calculations after such sur-
gery. Subjects who underwent glaucoma surgery
or who required more medication than just
prostaglandin were considered non-responders
in proportional IOP analyses. Safety assessment
in all eyes included: intraoperative and post-
operative adverse events; BCVA; automated
visual field; pachymetry; and findings from slit-
lamp, gonioscopic, and fundus (including optic
nerve assessment and C:D ratio) examinations.
All postoperative examinations were conducted
by the staff surgeon and glaucoma-trained staff
ophthalmologists. Subject follow-up will be
ongoing for 5 years.
Surgical Devices and Technique
The iStent Trabecular Micro-Bypass device
(Glaukos) is a single-piece, heparin-coated tita-
nium stent that is approximately 1.0 mm in
length and 0.33 mm in height with a ‘‘snorkel’’
bore diameter of 120 lm. The stent, shown in
Fig. 1, is inserted ab internally through the nasal
trabecular meshwork into Schlemm’s canal,
thus creating a bypass to improve aqueous
outflow via the natural physiologic pathway. In
this study, a second iStent was implanted in the
same manner approximately 2–3 clock hours
away from the first iStent. The iStent Supra
(Glaukos), shown in Fig. 2, is a suprachoroidal
stent made of polyethersulfone and titanium,
with a heparin-coated lumen of approximately
165 lm in diameter. Following uneventful
implantation of two iStent devices (as described
above), the iStent Supra is positioned ab inter-
nally through the trabecular meshwork into the
suprachoroidal space approximately halfway
between the iStents in this study, thereby
increasing aqueous outflow via the uveoscleral
pathway. The iStent and iStent Supra are each
pre-loaded on a single-use inserter which is
advanced through a single small temporal clear
Fig. 1 iStent trabecular micro-bypass Fig. 2 iStent Supra suprachoroidal micro-bypass
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corneal incision, thereby preserving tissue for
future glaucoma surgery should it be needed.
Following each surgical procedure, subjects
were placed on topical antibiotic medication
(tobramycin 0.3%) for 1 week and topical cor-
ticosteroid medication (dexamethasone 0.1%)
tapered over 4 weeks. At day 1 postoperative,
subjects began once-nightly topical pros-
taglandin (travoprost), which was continued for
the duration of the study except during wash-
out periods. Additional medication and/or
glaucoma surgery was to be instituted if a sub-
ject’s postoperative IOP exceeded 21 mmHg
and/or in the case of glaucomatous optic nerve
or visual field changes.
RESULTS
IOP and Medications
A total of 80 eyes of 80 qualified subjects con-
stituted the intent-to-treat (ITT) cohort and
underwent surgery, and 70 of these subjects
have completed 49 months of follow-up. Sub-
ject demographics and baseline ocular parame-
ters of the ITT group are summarized in Table 1,
and visual field measurements are shown in
Table 2. In brief, mean age was
65.2 ± 12.9 years, and all subjects had a history
of prior trabeculectomy. Consistent with
advanced disease, the mean preoperative C:D
ratio was 0.8 and average visual field mean
deviation was - 13 dB. Preoperative mean
medicated IOP was 22.0 ± 3.1 mmHg on a mean
of 1.2 ± 0.4 preoperative medications, and pre-
operative mean unmedicated (post-washout)
IOP was 26.4 ± 2.4 mmHg. The two most com-
mon preoperative medications, either as a sole
agent or combined with other ocular hypoten-
sive agents, were beta-adrenergic antagonists
(74% of eyes) and prostaglandin analogs (24%
of eyes).
Postoperatively, among all eyes not under-
going additional surgery during follow-up,
mean medicated IOP at all visits through
48 months was B 13.7 mmHg, as presented in
Fig. 3. This represents a C 37% mean reduction
from preoperative medicated IOP. In addition,
the mean unmedicated IOP at annual post-
washout visits ranged from 17.1 to 18.4 mmHg,
equating to a 30–35% reduction from preoper-
ative mean unmedicated IOP, and a 16–22%
reduction from preoperative mean medicated
IOP. Figure 4 displays the proportion of eyes
with IOP reduction C 20% on one postoperative
medication versus preoperative medicated IOP,
Table 1 Subject demographics and preoperative ocular
parameters
n 5 80
Age (years)
Mean (SD) 65.2 (12.9)
Range 27–86
Gender (n)
Male/female 34/46
Eye (n)
OD/OS 39/41
Preop medicated IOP (mmHg)
Mean (SD) 22.0 (3.1)
Cup-to-disc ratio
Mean (SD) 0.8 (0.1)
Range 0.5–1.0
# Preoperative medications
Mean (SD) 1.2 (0.4)
Preoperative medication type n (%)
Beta-blocker 59 (74%)
Prostaglandin analogue 19 (24%)
Carbonic anhydrase inhibitor 10 (13%)
Alpha agonist 7 (9%)
BCVA (decimal)
Mean (SD) 0.2 (0.4)a
Post-washout IOP (mmHg)
Mean (SD) 26.4 (2.4)
SD standard deviation, Preop preoperative, IOP intraocular
pressure, BCVA best-corrected visual acuity
a Due to ﬁnancial constraints and limited medication access,
many Armenian patients may undergo glaucoma surgery at an
earlier stage than is usually seen in more well-resourced settings.
This predisposition toward earlier ﬁltering surgery may help to
account for the more mild level of baseline BCVA loss than
typically would be expected in a refractory glaucoma population.
Additionally, given that glaucoma initially affects the more
peripheral visual ﬁeld, it is plausible for a patient cohort to have a
range of BCVA even in the setting of more advanced baseline VF
mean deviation measurements. Regardless of BCVA, the
advanced nature of disease is evidenced by the preoperative mean
C:D ratio (0.8) as well as preoperative visual ﬁeld mean deviation
(- 13.0 dB, as shown in Fig. 2)
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and also the proportion of eyes with C 20%
reduction in postoperative unmedicated IOP
versus preoperative unmedicated IOP. Both
proportions were high throughout follow-up,
ranging approximately 91–98% in the medi-
cated comparison and 92–97% in the unmedi-
cated comparison. The proportions of eyes with
IOP on one medication B 15 and B 18 mmHg
also remained high, and were 97 and 98%,
respectively, at the month 48 visit (Fig. 5).
Additional medication (in addition to
travoprost) and/or glaucoma surgery was to be
instituted if a subject’s postoperative IOP
exceeded 21 mmHg and/or in the case of glau-
comatous optic nerve or visual field changes.
Given these parameters, six total eyes required
additional medication by 3 months; these sub-
jects were included in analyses of mean IOP at
each visit (Fig. 3), and were considered non-re-
sponders in the proportional analyses (Figs. 4,
5). No medication was added in any other eye
for the remainder of follow-up.
Safety Assessment
There was one intraoperative report of inability
to implant the suprachoroidal stent due to
reduced visibility; this occurred after successful
implantation of two iStent devices, which
remained intact and resulted in no subsequent
sequelae. Otherwise, there were no intraopera-
tive adverse events, including no choroidal
effusion, hyphema, nor iridodialysis. Postoper-
atively, a total of 15 adverse events occurred: 12
reports of C 3 line drop in BCVA, and 3 non-
study-related deaths. Of the 12 eyes with
reduced BCVA, 1 was due to variable vision
from fluctuating visual field and 11 were due to
advancing cataract (of whom 10 underwent
cataract surgery and 1 had cataract surgery
pending). After cataract surgery, the IOP mea-
surements of these 10 patients were excluded
from IOP analyses. Importantly, no subjects
required additional glaucoma surgery during
the entire 4-year follow-up period.
Postoperative measures of central corneal
thickness, visual field mean deviation and pat-
tern standard deviation, and C:D ratio remained
approximately stable throughout follow-up, as
shown in Table 2. BCVA from screening to
month 48 also appeared generally stable, as
presented in Fig. 6.
DISCUSSION
The treatment of refractory glaucoma presents
complex challenges for surgeons and patients.
Therapeutic options traditionally have included
maximizing the number of medications and/or
undergoing a second trabeculectomy or aque-
ous shunt surgery as disease advances. Medica-
tions have coexistent side effects, costs, and/or
toxicities [40–42], and their effectiveness is
limited by the widely-known low adherence
level of patients to medical therapy [43–46].
Filtering surgery carries a lifelong risk of com-
plications such as endophthalmitis, hypotony,
bleb infections, bleb leaks, and fibrosis [21–30].
Meanwhile, iStent technology has predomi-
nantly been used in cases of mild to moderate
OAG, where it has demonstrated long-term
effectiveness and excellent safety [3–6, 9–20].
However, several recent reports have shown
that the iStent may also be beneficial in cases of
more advanced disease [7, 8, 31–33]. Given the
difficulty of treating refractory disease, and the
risk profile associated with more invasive tradi-
tional interventions, the present study offers
Table 2 Screening and month 48 cup-to-disc ratio, visual
ﬁeld, and central corneal thickness
Screening Month
48
n 80 70
Cup-to-disc ratio, mean (SD) 0.8 (0.1) 0.8 (0.1)
Visual ﬁeld-MD (dB), mean (SD) - 13.0
(8.6)
- 13.2
(8.5)
Visual ﬁeld-PSD (dB), mean (SD) 6.0 (2.7) 5.8 (2.6)
Central corneal thickness (lm),
mean (SD)
523.1
(37.9)
526.4
(33.3)
SD standard deviation, MD mean deviation, PSD pattern
standard deviation
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insight into a novel minimally invasive treat-
ment approach for these patients.
To our knowledge, this is the first study to
evaluate trabecular micro-bypass in an entirely
refractory patient population; all patients had
history of prior trabeculectomy and had IOP
above goal despite 1–3 medications. In addi-
tion, it is the first study to introduce a treatment
strategy using three treatment modalities (tra-
becular stent, suprachoroidal stent, and topical
prostaglandin) to target both trabecular and
uveoscleral outflow. In the cohort of subjects
followed through 48 months, the vast majority
of eyes (approximately 94–98%) achieved post-
operative IOP on one medication
of B 18 mmHg at all visits, which is clinically
significant, given that visual field progression is
delayed when IOP consistently is maintained
below 18 mmHg, as demonstrated in the land-
mark Advanced Glaucoma Intervention Study
[47].
In addition, a significant strength of this
study was the completion of annual postopera-
tive medication washouts, which isolate the
action of trabecular and suprachoroidal stents
alone, without the effect of medication. At
these post-washout visits (months 13, 25, 37,
and 49), mean unmedicated IOPs remained
near the 18-mmHg threshold, at 17.1–
18.4 mmHg, representing a 30–35% reduction
from preoperative mean unmedicated IOP, and
a 16–22% reduction from preoperative mean
medicated IOP. This IOP level suggests that, in
the absence of a study protocol, some patients
might be able to achieve target pressures and be
managed without medications. This adds value,
given that medications’ effectiveness may be
limited by side effects, toxicities, cost, and
patient adherence [40–46].
Based on IOP measurements during the
study’s washout periods, it appears that the
prostaglandin contributed approximately
4 mmHg of IOP lowering, equaling a reduction
of approximately 15% from mean baseline
unmedicated IOP. This decrease is less substan-
tial than the * 30% IOP reductions typically
expected with prostaglandin analogs [48]. This
discrepancy likely reflects the refractory nature
Fig. 3 Mean IOP over time. *Unmedicated IOP (at
months 13, 25, 37, 49) was assessed after 1-month
washout. aExcludes data after additional surgery (either
glaucoma surgery [n = 0] or cataract surgery [n = 10]).
IOP Intraocular pressure, SD Standard deviation, SCR
screening, BL baseline, M month
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of disease in these eyes with prior filtering sur-
gery and medication use. The fact that the
iStents and iStent Supra yielded sizable IOP
reductions in this population is thus even more
noteworthy.
The safety parameters observed in this study
were favorable, including stable BCVA, visual
fields, C:D ratio, and corneal pachymetry over
the course of follow-up. There was one intra-
operative report of inability to implant the
suprachoroidal stent, but otherwise no intra-
operative adverse events occurred. The most
common postoperative adverse event was BCVA
decrease due to cataract progression, which
occurred in approximately 16% of eyes (11 of 70
by 4 years). However, this rate of cataract pro-
gression is lower than that of trabeculectomy,
which is estimated to cause cataract in over 50%
of subjects within 5 years [49]; furthermore, the
study’s cataract cases were successfully addres-
sed with cataract surgery. There were no reports
of suprachoroidal hemorrhage, persistent
hypotony, infection, dysesthesia, hyphema, or
iridodialysis. Over the course of follow-up, six
eyes were prescribed a second medication, but
all other eyes remained on travoprost alone. No
eyes underwent secondary glaucoma surgery
throughout follow-up. This is especially signifi-
cant given that many of these patients likely
would otherwise have undergone such a sur-
gery. These filtering surgeries have a well-doc-
umented ongoing annual risk of complications
[21–30], which places a considerable cumulative
burden on patients with this lifelong disease.
Thus, even if some of these patients ultimately
undergo additional intervention in the future,
the delay-to-surgery of 4 or more years is valu-
able in itself by reducing this cumulative risk.
We acknowledge certain limitations in this
nonrandomized, open-label study. All subjects
were Caucasian, all visits occurred at a single
site, and mean diurnal IOP was not measured at
all visits. The relatively low values for IOP vari-
ance observed in this study appear consistent
with variance in several prior reports of iStent
technology [7, 50, 51]. There was no control
arm; however, like in many other studies of
standalone interventions, we considered it rea-
sonable for subjects’ preoperative data to serve
as their own control. In addition, given that this
refractory population already had failed filter-
ing surgery and medication, no standard next-
Fig. 4 Proportional analysis of postoperative IOP reduc-
tion C 20%. *Unmedicated IOP (at months 13,
25, 37, 49) was assessed after 1-month washout. aExcludes
data after cataract surgery (n = 10). Subjects with
additional glaucoma surgery (n = 0) or addition of a
second ocular hypotensive medication (n = 6) were con-
sidered non-responders. IOP Intraocular pressure, Med
medication, Preop preoperative, M month
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step treatment was readily apparent. And third,
since these refractory eyes were vulnerable to
optic nerve damage and visual field
deterioration, a control group of minimal
intervention would not have been clinically or
ethically appropriate.
Fig. 5 Proportional analysis of postoperative IOP B 15
and B 18 mmHg. aExcludes data after cataract surgery
(n = 10). Subjects with additional glaucoma surgery
(n = 0) or addition of a second ocular hypotensive
medication (n = 6) were considered non-responders. IOP
Intraocular pressure, Med medication, M month
Fig. 6 Preoperative versus month 48 best-corrected visual acuity (BCVA)
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Given that all subjects underwent a com-
bined treatment (two iStent trabecular stents,
one iStent Supra suprachoroidal stent, and
postoperative prostaglandin), it is not possible
to quantify the isolated effect of each specific
component on IOP. However, this study’s
simultaneous use of surgical and medical treat-
ment has precedence in the literature, such as in
the landmark Early Manifest Glaucoma Trial
[52]. Additionally, the annual medication
washouts provide an estimate of the devices’
effect alone, which is a C 30% reduction in IOP.
In future investigations, several alternative
study designs could be considered in order to
isolate the effects of each treatment modality.
One such study design could have been a step-
wise addition of one treatment at a time; how-
ever, this would have subjected subjects to
additional surgery, and also might delay arrival
at a sufficiently safe IOP for these refractory
eyes. A second alternative design could be a
multi-armed trial comparing different treat-
ment combinations (for example: trabecular
stents ? suprachoroidal stent; trabecular
stents ? prostaglandin; suprachoroidal
stent ? prostaglandin; trabecular stents alone;
or suprachoroidal stent alone); however, this
also could produce an unsafe delay in reaching
appropriate IOP, and would have required a
much larger cohort to allow for meaningful
comparisons. A third alternative design could
be initial treatment with two iStents and
travoprost, with subsequent ‘‘crossover’’ or
‘‘escape’’ to iStent Supra in cases of insufficient
IOP reduction.
In this report, we have presented 4 years of
follow-up data for this ongoing study, but full
results with extended follow-up out to 61
months will provide even more robust insights
into long-term outcomes for refractory disease
under this treatment methodology. In addition,
other directions for future investigation could
include structural and functional testing to
quantify glaucoma severity (possibly using
novel imaging techniques), or evaluation of this
treatment methodology in eyes with pseu-
doexfoliative glaucoma. And finally, the present
study had a single treatment arm consisting of
three interventions; however, in order to
determine definitively whether combined MIGS
devices are a suitable alternative to additional
incisional surgery, a randomized controlled
study would be needed to directly compare
traditional filtering surgery with combined tra-
becular/suprachoroidal stents and pros-
taglandin in these refractory eyes.
CONCLUSIONS
In conclusion, this study provides insights into
a novel, minimally invasive technique and
treatment regimen for the control of refractory
glaucoma: specifically, the combined use of two
trabecular micro-bypass stents, a suprachoroidal
stent, and postoperative prostaglandin. Follow-
ing this intervention, outcomes through 4 years
demonstrate meaningful IOP and medication
reductions, favorable safety, and avoidance of
additional filtering surgery in the vast majority
of refractory cases. These long-term outcomes
indicate that the combination of multiple
minimally invasive devices with medication
may have a role in treating unresponsive or
under-controlled refractory primary OAG, even
while preserving ocular tissue for additional
surgeries should they be warranted.
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